Scinai Moves to Regain Nasdaq Compliance with 1-for-10 ADS Ratio Change
SCNI is trading near its 52-week low of $0.215 (8.9% above the low) on light trading volume (0.3× avg).
Summary
Scinai Immunotherapeutics will implement a 1-for-10 ADS ratio change on August 21, 2026, to boost its per-ADS price and regain compliance with Nasdaq's $1.00 minimum bid rule.
Key Events · Corporate Governance and Compliance · SCNI
-
ADS Ratio Change Announced
Effective August 21, 2026, the ADS ratio changes from 1:4,000 to 1:40,000 ordinary shares, equivalent to a 1-for-10 reverse split of ADSs.
-
Nasdaq Compliance Objective
The change is intended to increase the per-ADS trading price and regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per ADS.
-
No Shareholder Action Required
ADS holders do not need to take any action; fractional entitlements will be aggregated and sold by the depositary bank, with net cash proceeds distributed to holders.
-
New CUSIP Number
The ADSs will trade under a new CUSIP number, 09073Q402, on the Nasdaq Capital Market under the symbol SCNI.
Analysis · SCNI · Life Sciences
To lift its per-ADS price above the $1.00 Nasdaq minimum bid requirement, Scinai is adjusting its ADS ratio from 1:4,000 to 1:40,000, effectively a 1-for-10 reverse split of its ADSs, effective August 21, 2026. No shareholder action is needed, but the change underscores the listing pressure the company faces and its efforts to avoid delisting.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 29.7% of the 1516 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCNI was trading at $0.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $932.5K. The 52-week trading range was $0.21 to $1.79. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.